Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 6:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Neoplasms With Mesothelin Expression Clear all

Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

NCT06051695

View directory record Official record

Conditions: Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
Interventions: A2B694, A2B543, xT CDx with HLA-LOH Assay; Biological · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 12
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more

Source: ClinicalTrials.gov public record

Updated May 18, 2026 · Synced May 21, 2026, 6:18 PM EDT

Recruiting Phase 1 Interventional

CT-95 in Advanced Cancers Associated With Mesothelin Expression

NCT06756035

View directory record Official record

Conditions: Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced, Pancreatic Adenocarcinoma Advanced or Metastatic, Lung Adenocarcinoma Metastatic, Cholangiocarcinoma Advanced, Cholangiocarcinoma Non-resectable, Mesothelin-expressing Advanced Cancers, Mesothelin-positive Advanced Malignant Solid Tumors, Colorectal Cancer
Interventions: CT-95; Drug
Lead sponsor: Context Therapeutics Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Denver, Colorado • Chicago, Illinois • Grand Rapids, Michigan + 4 more

Source: ClinicalTrials.gov public record

Updated Jul 30, 2025 · Synced May 21, 2026, 6:18 PM EDT

Recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

NCT07030907

View directory record Official record

Conditions: Ovarian Cancer Recurrent, Ovarian Cancer, Platinum Resistant Ovarian Cancer
Interventions: OPB-101; Biological
Lead sponsor: Outpace Bio, Inc.; Industry
Eligibility: 18 Years and older · Female only

Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 4
States / cities: Detroit, Michigan • Minneapolis, Minnesota • Buffalo, New York + 1 more

Source: ClinicalTrials.gov public record

Updated Dec 17, 2025 · Synced May 21, 2026, 6:18 PM EDT

Completed Phase 1 Interventional Results available

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

NCT04034238

View directory record Official record

Conditions: Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma, Cholangiocarcinoma, Extrahepatic, Adenocarcinoma, Pancreatic
Interventions: LMB-100, Tofacitinib, Mesothelin Expression; Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Jul 31, 2023 · Synced May 21, 2026, 6:18 PM EDT

Completed Phase 1 Interventional

Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression

NCT03872206

View directory record Official record

Conditions: Advanced Cancers Associated With Mesothelin Expression
Interventions: HPN536 Fixed IV 6 to 560 ng/kg, HPN536 1 Prime Step IV 600-1200 ng/kg Target, 2 Prime Step IV 900-14000 ng/kg Target; Biological
Lead sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older

Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 16
States / cities: Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 12 more

Source: ClinicalTrials.gov public record

Updated Jun 6, 2024 · Synced May 21, 2026, 6:18 PM EDT

Completed Phase 1 Interventional Results available

Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors

NCT04727554

View directory record Official record

Conditions: Advanced Solid Tumors
Interventions: AMG 994, AMG 404; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years

Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Duarte, California • Detroit, Michigan • Cleveland, Ohio + 2 more

Source: ClinicalTrials.gov public record

Updated Jan 5, 2025 · Synced May 21, 2026, 6:18 PM EDT